NASDAQ · GRAL
GRAIL Inc.
Healthcare · Medical - Diagnostics & Research
$98.41▲ 21.83% ($17.63)today
As of 9:55 AM ET
Market cap
$4.22B
P/E
-10.09
EPS (TTM)
-$9.08
Next earnings
Nov 11, 2026
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 121.79% over the last year. Revenue grew 23.07% over the trailing twelve months. Operating margin moved from -471.32% to -338.4%. Free cash flow grew 20.58% over the trailing twelve months.
What the market seems to be pricing
The stock is trading toward the richer end of its historical P/S range (100th percentile) while business metrics are improving. More of the upside is already embedded in the multiple now.
What would invalidate this read
Operating margin is at -338.4% — continued expansion would be needed to justify the premium. Revenue growth of 23.07% is encouraging, but any deceleration puts the stretched multiple at risk. This read changes if revenue, margins, and cash flow continue to improve faster than expected — in that case the richer multiple could still prove conservative.
Performance
Return analysis
Company profile
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally.
Market multiples
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
4
Buy
3
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 11, 2026
Q4 FY26 · EPS est -$2.51 · Revenue est $44.34M
View